Uncategorized

Comanche Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for CBP-4888, an siRNA Investigational Therapy for the Treatment of Preeclampsia

Comanche Biopharma Corp., a biopharmaceutical company, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for Comanche’s novel, siRNA therapy to treat preeclampsia.

Comanche Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for CBP-4888, an siRNA Investigational Therapy for the Treatment of Preeclampsia Read More »

Scroll to Top